Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

MLA

Shinsuke Suzuki, et al. “Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.” Medicina, vol. 57, no. 11, Oct. 2021, p. 1151. EBSCOhost, https://doi.org/10.3390/medicina57111151.

APA

Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, & Takechiyo Yamada. (2021). Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Medicina, 57(11), 1151. https://doi.org/10.3390/medicina57111151

Chicago

Shinsuke Suzuki, Satoshi Toyoma, Yohei Kawasaki, Koh Koizumi, Nobuko Iikawa, Kazuhiro Shiina, Tentaro Endo, Tomoe Abe, Teppei Kouga, and Takechiyo Yamada. 2021. “Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.” Medicina 57 (11): 1151. doi:10.3390/medicina57111151.